The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk
Open accessAbstract
Purpose: The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal experience with LCIS to evaluate factors associated with breast cancer risk. Patients and Methods: Patients participating in surveillance after an LCIS diagnosis are observed in a prospectively maintained database. Comparisons were made among women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009. Results: One thousand sixty patients with LCIS without concurrent breast cancer were identified. Median age at LCIS diagnosis was 50 years (range, 27 to 83 years). Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or without (n = 831) chemoprevention. At a median follow-up of 81 months (range, 6 to 368 months), 150 patients developed 168 breast cancers (63% ipsilateral, 25% contralateral, 12% bilateral), with no dominant histology (ductal carcinoma in situ, 35%; infiltrating ductal carcinoma, 29%; infiltrating lobular carcinoma, 27%; other, 9%). Breast cancer incidence was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001). In multivariable analysis, chemoprevention was the only clinical factor associated with breast cancer risk (hazard ratio, 0.27; 95% CI, 0.15 to 0.50). In a subgroup nested case-control analysis, volume of disease, which was defined as the ratio of slides with LCIS to total number of slides reviewed, was also associated with breast cancer development (P = .008). Conclusion: We observed a 2% annual incidence of breast cancer among women with LCIS. Common clinical factors used for risk prediction, including age and family history, were not associated with breast cancer risk. The lower breast cancer incidence in women opting for chemoprevention highlights the potential for risk reduction in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Cited by
Breast Cancer Epidemiology and Risk Factors
ROJAS, K., & STUCKEY, A. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000239 · Cited by 576
Hereditary diffuse gastric cancer: updated clinical practice guidelines
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., Harris, K. L., Hoogerbrugge, N., Oliveira, C., van der Post, R. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30219-9 · Cited by 491
Contrast‐enhanced MRI for breast cancer screening
Mann, R. M., Kuhl, C. K., & Moy, L. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26654 · Cited by 356
Counselling framework for moderate-penetrance cancer-susceptibility mutations
Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., Offit, K., & Robson, M. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.90 · Cited by 314
Metadata
- Authors
- King, T. A., Pilewskie, M., Muhsen, S., Patil, S., Mautner, S. K., Park, A., Oskar, S., Guerini-Rocco, E., Boafo, C., Gooch, J. C., De Brot, M., Reis-Filho, J. S., Morrogh, M., Andrade, V. P., Sakr, R. A., & Morrow, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-20
- Volume
- 33
- Issue
- 33
- Pages
- 3945-3952
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1940799857
- Cited by
- 208
- References
- 1
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. https://app.cochat.ai/papers/10.1200/jco.2015.61.4743
- The paper
- King, T. A., Pilewskie, M., Muhsen, S., Patil, S., Mautner, S. K., Park, A., Oskar, S., Guerini-Rocco, E., Boafo, C., Gooch, J. C., De Brot, M., Reis-Filho, J. S., Morrogh, M., Andrade, V. P., Sakr, R. A., & Morrow, M. (2015). Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.61.4743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.